摘要
生物素 -亲和素介导的肿瘤靶向治疗是近几年来肿瘤早期诊断、治疗研究的热点。将包封有 TNFα的壳聚糖微球生物素化 ,以生物素化无唾液酸胎球蛋白为导向系统 ,采用“三步法”研究了微球体外抗肿瘤毒性实验。结果表明 :生物素化壳聚糖微球对体外培养的肝癌细胞 SMMC- 772 1有显著的抑制作用 (抑制率为 6 0 .8% ,P<0 .0 1)。
Chitosan microspheres loading TNFα were biotinylated by BNHS. The antitumor activity against SMMC 7721 was studied in vitro by “three step” method, which employed biotinylated asialofetuin as a pretargeting agent. It was found that biotinylated chitosan microspheres could obviously inhibit the hepatocellular carcinoma cell line SMMC 7721 cultured in vitro with the inhibitory rate being 60 8 % ( P <0 01). The results demonstrated that biotinylated asialofetuin avidin biotinylated microspheres could be used for targeted therapy of tumor.
出处
《同济医科大学学报》
CSCD
2000年第4期301-303,共3页
Acta Universitatis Medicinae Tongji
基金
国家自然科学基金!资助项目 (No. 39990 5 70 )
